Cargando…
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study
BACKGROUND: Conteltinib (CT-707) is a potent second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) showing promising anti-tumor activities in preclinical studies. This study aimed to assess the safety, pharmacokinetic (PK), and efficacy of conteltinib in patients with AL...
Autores principales: | Xing, Puyuan, Zhao, Qian, Zhang, Li, Wang, Hanping, Huang, Dingzhi, Hu, Pei, Sun, Yinghui, Shi, Yuankai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694544/ https://www.ncbi.nlm.nih.gov/pubmed/36424628 http://dx.doi.org/10.1186/s12916-022-02646-0 |
Ejemplares similares
-
SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells: SY-707 is an ALK/FAK/IGF1R inhibitor
por: Liu, Ping, et al.
Publicado: (2022) -
Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2018) -
Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial
por: Ma, Yuxiang, et al.
Publicado: (2022) -
Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
por: Zou, Zihua, et al.
Publicado: (2022) -
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
por: Yang, Yunpeng, et al.
Publicado: (2023)